Caribou Biosciences to close after failing to fund CAR-T lymphoma trial
Caribou Biosciences announced it will shut down because it could not secure financing for a Phase 3 trial of its off-the-shelf CAR-T therapy for advanced B-cell non-Hodgkin lymphoma.
The Berkeley-based biotech, co-founded by CRISPR pioneer Jennifer Doudna, said it will cease operations after being unable to raise the capital needed for a late-stage study of its CRISPR-based CAR-T candidates, including vispa-cel. The company had worked with the Food and Drug Administration to finalize the trial design, but funding gaps forced the decision. CEO Rachel Haurwitz confirmed the closure to reporters.
Why it matters
The shutdown highlights the financing challenges facing advanced gene-editing therapies and may slow progress in lymphoma treatment.
In this story
